Dimitra Micha is the group leader of the Center for Connective Tissue Diseases which has as main focus the study of osteogenesis imperfecta, and other monogenetic disorders of skeletal fragility and dysplasia. Her research aims the identification of new genetic causes and the development of meaningful therapy which is still lacking for these disorders. She has discovered several genes (KDELR2, PLS3) which have improved the molecular diagnosis of these patients in addition to providing new insight in the underlying disease pathology. Dimitra was promoted in 2010 on clinical pharmacology in Manchester UK; she was established as head of the research group in 2016 which has resulted since then in several grants and PhD promotions.